News >

Future of Immunotherapy in Ovarian Cancer to Include Combinations

Angelica Welch
Published: Friday, Dec 22, 2017

Bradley J. Monk, MD

Bradley J. Monk, MD
Prior studies of single-agent immunotherapy with checkpoint inhibitors have generally failed to show benefit in patients with ovarian cancer. This has not deterred investigators though, as there are currently 5 phase III clinical trials evaluating checkpoint blockade in combination regimens.

, Bradley J. Monk, MD, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, discussed these pivotal trials, as well as the potential for immunotherapy in ovarian cancer.

OncLive: Where are we with immunotherapy in ovarian cancer?

Monk: We are all aware of the emerging immuno-oncology data across all solid tumors, and even Hodgkin lymphoma. There are currently no FDA-approved immunotherapy agents in gynecologic cancers, except microsatellite instability-high or mismatch-repair deficient endometrial cancers.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x